INS and type 1 diabetes mellitus: New therapeutic assumptions for type 1 of diabetes guaranteeing the protection and regeneration of endogenous islets or based on the treatment of primary autoimmunity through selective modulation of essential immune cells may exclude the current standard treatment limited to regimen glycemic control and force systematic injections of endogenous insulin.